Clinical Trial Update: Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

This document provides an update on a Phase 3 clinical trial evaluating a combination of fulvestrant, everolimus, and exemestane for metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Everolimus (everolimus)
• Exemestane (Exemestane)
• Fulvestrant (fulvestrant)

Snippet

Sponsor: Consorzio Oncotech | Conditions: Metastatic Breast Cancer, Breast Cancer | Phase 3 | Status: UNKNOWN